A systematic review and integrative approach to decode the common molecular link between levodopa response and Parkinson's disease

scientific article published on 19 September 2017

A systematic review and integrative approach to decode the common molecular link between levodopa response and Parkinson's disease is …
instance of (P31):
scholarly articleQ13442814
meta-analysisQ815382

External links are
P6179Dimensions Publication ID1091840059
P356DOI10.1186/S12920-017-0291-0
P8608Fatcat IDrelease_3pc63flr2zfsxftemnjoyilguq
P932PMC publication ID5606117
P698PubMed publication ID28927418

P50authorRitushree KukretiQ87148604
P2093author name stringPuneet Talwar
Suman S Kushwaha
Shrikant Kukreti
Chitra Rawat
Debleena Guin
Manish Kumar Mishra
P2860cites workGenotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's diseaseQ64763354
Genetic polymorphism of Angiotensin-Converting Enzyme is not associated with the development of Parkinson's disease and of L-dopa-induced adverse effectsQ64939817
G/A1947 polymorphism in catechol-O-methyltransferase (COMT) gene in Parkinson's diseaseQ67211130
Research diagnostic criteria for Parkinson's diseaseQ68601645
Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's diseaseQ79464324
Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's diseaseQ79759867
Etiology and pathogenesis of Parkinson's diseaseQ84231134
Catechol-O-methyltransferase Val158Met polymorphism: modulation of wearing-off susceptibility in a Chinese cohort of Parkinson's diseaseQ87536077
Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's diseaseQ21144949
Parkinson's disease: clinical features and diagnosisQ22242021
Evaluation of the potential excess of statistically significant findings in published genetic association studies: application to Alzheimer's diseaseQ24289214
Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson diseaseQ24596763
Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studiesQ24606055
Genome-wide association study reveals genetic risk underlying Parkinson's diseaseQ24646654
Dopamine D5 receptor gene polymorphism and the risk of levodopa-induced motor fluctuations in patients with Parkinson's diseaseQ28205539
Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's diseaseQ28244731
Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2.Q28262863
Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PDQ28375036
Dopamine depletion alters phosphorylation of striatal proteins in a model of ParkinsonismQ28579756
Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's diseaseQ28943440
Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21.Q29417095
Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's diseaseQ29614900
STRING v10: protein-protein interaction networks, integrated over the tree of lifeQ29615545
Identification of a novel Parkinson's disease locus via stratified genome-wide association studyQ30571934
Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control studyQ31932059
Role of the ubiquitin proteasome system in Parkinson's diseaseQ33307874
Systematic reviews of genetic association studies. Human Genome Epidemiology NetworkQ33414801
Parkinson's Disease Society Brain Bank, London: overview and researchQ33463550
Genome-wide mapping of IBD segments in an Ashkenazi PD cohort identifies associated haplotypesQ33991709
PharmGKB: the Pharmacogenetics Knowledge BaseQ34010656
Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson's diseaseQ34326909
Dopamine transporter SLC6A3 genotype affects cortico-striatal activity of set-shifts in Parkinson's diseaseQ34399250
Interactions of CaMKII with dopamine D2 receptors: roles in levodopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's ratsQ34417485
Diagnostic criteria for Parkinson diseaseQ34489839
Levodopa and the progression of Parkinson's diseaseQ34553278
Multiple roles for Arf6: sorting, structuring, and signaling at the plasma membraneQ35197211
Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's diseaseQ35821201
Insulin-Like Growth Factor 1 (IGF-1) in Parkinson's Disease: Potential as Trait-, Progression- and Prediction Marker and Confounding FactorsQ35953962
???Q64763388
???Q64764709
???Q64797105
The genetics of Parkinson's disease: progress and therapeutic implicationsQ36626825
ARF6 and GASP-1 are post-endocytic sorting proteins selectively involved in the intracellular trafficking of dopamine D₂ receptors mediated by GRK and PKC in transfected cellsQ36681759
The role of common genetic risk variants in Parkinson diseaseQ36941992
WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013Q36954017
Variation in dopamine genes influences responsivity of the human reward systemQ37062116
STrengthening the REporting of Genetic Association studies (STREGA)--an extension of the STROBE statementQ37314650
Pharmacogenetics of Parkinson's disease - through mechanisms of drug actions.Q37583417
Clinical and pathological features of Parkinson's diseaseQ38213626
Parkinson's disease pharmacogenomics: new findings and perspectives.Q38241678
The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanationsQ38510678
Essential myoclonus and myoclonic dystoniaQ41018229
Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's diseaseQ41168222
Editorial: Parkinson's disease: cell vulnerability and disease progressionQ41846573
NMDA receptor genotypes associated with the vulnerability to develop dyskinesiaQ42072420
Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients.Q42708909
The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesiaQ42792207
Impaired transmethylation potential in Parkinson's disease patients treated with L-DopaQ43243392
Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patientsQ43270106
Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patientsQ43592846
Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicityQ44221551
L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphismQ44471611
Polymorphisms in the dopamine transporter gene are associated with visual hallucinations and levodopa equivalent dose in Brazilians with Parkinson's disease.Q44687266
Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutationQ44782063
Do tardive dyskinesia and L-dopa induced dyskinesia share common genetic risk factors? An exploratory study.Q45007058
Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's diseaseQ45301027
Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure.Q45345781
Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions.Q46003760
Motor complications in patients form the German Competence Network on Parkinson's disease and the DRD3 Ser9Gly polymorphismQ46057259
Motor impulsivity in Parkinson disease: associations with COMT and DRD2 polymorphismsQ46205987
Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's diseaseQ46407825
Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory studyQ46433089
Functional COMT variant predicts response to high dose pyridoxine in Parkinson's diseaseQ46555889
Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease.Q46910776
A Novel Parkinson's Disease Drug Candidate with Potent Anti-neuroinflammatory Effects through the Src Signaling PathwayQ48518599
BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease.Q48852969
Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's diseaseQ48880365
The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.Q50547059
Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson's disease.Q51172907
Coenzyme Q10, hyperhomocysteinemia and MTHFR C677T polymorphism in levodopa-treated Parkinson's disease patients.Q51418735
Implications of small effect sizes of individual genetic variants on the design and interpretation of genetic association studies of complex diseases.Q53008274
Visual hallucinations in Parkinson's disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes.Q53287838
Association of UDP-glucuronosyltransferase 1A9 polymorphisms with adverse reactions to catechol-O-methyltransferase inhibitors in Parkinson's disease patients.Q54313392
Study Quality Assessment in Systematic Reviews of Research on Intervention EffectsQ57970160
Genetic basis for individual variations in pain perception and the development of a chronic pain conditionQ60628070
Is there a role for ADORA2A polymorphisms in levodopa-induced dyskinesia in Parkinson's disease patients?Q61648204
DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson’s disease patientsQ61648243
The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's diseaseQ62588922
P433issue1
P921main subjectlevodopaQ300989
P304page(s)56
P577publication date2017-09-19
P1433published inBMC Medical GenomicsQ15754662
P1476titleA systematic review and integrative approach to decode the common molecular link between levodopa response and Parkinson's disease
P478volume10